Artificial oxygen carriers as a possible alternative to red cells in clinical practice
Keywords:
Hemoglobins, Anemia, Blood, Blood transfusion, Blood substitutesAbstract
Fluid resuscitation is intended to eliminate microcirculatory disorders and restore adequate tissue oxygenation. The safety limits for a restrictive transfusion policy are given by patients’ individual tolerance of acute normovolemic anemia. Artificial oxygen carriers based on perfluorocarbon or hemoglobin are attractive alternatives to allogenic red blood cells. There are many risks involved in allogenic blood transfusions and they include transmission of infections, delayed postoperative wound healing, transfusion reactions, immunomodulation and cancer recurrence. Regardless of whether artificial oxygen carriers are available for routine clinical use, further studies are needed in order to show the safety and efficacy of these substances for clinical practice.
Downloads
References
Brunskill S, Prowse C, Garrioch M, et al. Blood substitutes for avoiding allogeneic blood transfusion. The Cochrane Library. Available from: http://mrw.interscience.wiley.com/co- chrane/clsysrev/articles/CD004894/frame.html. Accessed in 2009 (Feb 3).
Henkel-Honke T, Oleck M. Artificial oxygen carriers: a current review. AANA J. 2007;75(3): 205-11.
Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol. 1949;1(7):469-89.
Nouwairi NS. The risks of blood transfusions and the shortage of supply leads to the quest for blood substitutes. AANA J. 2004;72(5):359-64.
Creteur J, Vincent JL. Hemoglobin solutions. Crit Care Med. 2003;31(12 Suppl):S698-707.
Jahr JS, Walker V, Manoochehri K. Blood substitutes as pharmacotherapies in clinical prac- tice. Curr Opin Anaesthesiol. 2007;20(4):325-30.
Pape A, Habler O. Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaes- thesiol. 2007;21(2):221-39.
Messmer KF. Acceptable hematocrit levels in surgical patients. World J Surg. 1987;11(1): 41-6.
Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anes- thesiology. 2000;93(1):242-55.
Habler OP, Messmer KF. The physiology of oxygen transport. Transfus Sci. 1997;18(3):425-35.
Cain SM. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol. 1977;42(2):228-34.
Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348(9034):1055-60.
Brander L, Reil A, Bux J, Taleghani BM, Regli B, Takala J. Severe transfusion-related acute lung injury. Anesth Analg. 2005;101(2):499-501.
Landers DF, Hill GE, Wong KC, Fox IJ. Blood transfusion-induced immunomodulation. Anesth Analg. 1996;82(1):187-204.
Weber EW, Slappendel R, Prins MH, van der Schaaf DB, Durieux ME, Strümper D. Periope- rative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg. 2005;100(5):1416-21.
Habler O, Pape A, Meier J, Zwissler B. Künstliche Sauerstoffträger als Alternative zur Blut- transfusion. [Artificial oxygen carriers as an alternative to red blood cell transfusion]. Anaes- thesist. 2005;54(8):741-54.
Spahn DR, Kocian R. The place of artificial oxygen carriers in reducing allogeneic blood trans- fusions and augmenting tissue oxygenation. Can J Anaesth. 2003;50(6 Suppl):S41-7.
Wahr JA, Trouwborst A, Spence RK, et al. A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg. 1996;82(1):103-7.
Spahn DR, Leone BJ, Reves JG, Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg. 1994;78(5):1000-21.
Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg. 1996;82(2):390-405.
Stowell CP. What happened to blood substitutes? Transfus Clin Biol. 2005;12(5):374-9.
Moore EE. Blood substitutes: the future is now. J Am Coll Surg. 2003;196(1):1-17.
Migita R, Gonzales A, Gonzales ML, Vandegriff KD, Winslow RM. Blood volume and cardiac index in rats after exchange transfusion with hemoglobin-based oxygen carriers. J Appl Phy- siol. 1997;82(6):1995-2002.
Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des. 2005; 11(31):4099-114.
Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized he- moglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998;187(2):113-20; discussion 120-2.
Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology. 2002;97(6):1338-49.
Hable O, Kleen M, Pape A, Meisner F, Kemming G, Messmer K. Diaspirin-crosslinked hemo- globin reduces mortality of severe hemorrhagic shock in pigs with critical coronary stenosis. Crit Care Med. 2000;28(6):1889-98.
Issues in Emerging Health Technologies. Oxygen carriers (“blood substitutes”). Canadian Agency for Drugs and Technologies in Health. 2001;21:1-6. Available from: http://www. acmts.ca/media/pdf/151_oxygencarriers_cetap_e.pdf. Accessed in 2009 (Feb 3).
